|Type||Public (NASDAQ: SLXP)|
|Headquarters||Raleigh, North Carolina, United States|
|Key people||Carolyn J. Logan CEO
Adam C. Derbyshire CFO
Salix Pharmaceuticals, Inc. is a specialist American pharmaceutical company. It develops drugs and medical devices that prevent and treat various gastrointestinal disorders. It is listed in the Russell 2000 index. This company is listed as having the most revenue per employee (at 1,400,846) by Bizjournals.com.
Salix Pharmaceuticals was founded in 1989, based in Raleigh, North Carolina.
On October 20, 2010 Salix Pharmaceuticals signed a strategic global agreement with Photocure for Lumacan. Lumacan is a photodynamic colorectal diagnostic intended to significantly improve the detection of precancerous and cancerous lesions in the colon through fluorescence diagnosis. In addition to the development of Lumacan for colorectal cancer. Salix has the exclusive right to explore and develop products for additional indications involving the diagnosis of gastrointestinal dysplasia and cancer
- "Company Overview of Salix Pharmaceuticals Ltd". Retrieved 2012-05-03.
- Salix Pharmaceuticals Board Unanimously Recommends Rejection of Axcan's Revised Offer. Business Wire, May 27, 2003.
- http://photocure.com/Pressmedia/News/Agreement-with-Salix-Pharmaceuticals-for-Lumacan/ Photocure signs agreement with Salix Pharmaceuticals for Lumacan™
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|